Please check your internet connection and try again.
# Durveqtix (fidanacogene elaparvovec)
## Overview
Durveqtix is an adeno-associated virus (AAV) vector-based gene therapy designed to deliver a functional copy of the *F9* gene to the liver. This allows for the endogenous production of Factor IX in patients with Hemophilia B, potentially eliminating the need for routine prophylactic factor replacement.
## Primary Indications
Treatment of adults (18 years and older) with moderately severe to severe hemophilia B (congenital Factor IX deficiency) who are currently using Factor IX prophylactic therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes.
## Adult Dosing
The recommended dose is **5 x 10¹¹ vector genomes (vg) per kilogram** of body weight, administered as a single-dose, intravenous infusion.
## Pediatric Dosing
**Not established.** Efficacy and safety have not been evaluated in pediatric patients. Use in patients under 18 years of age is not currently indicated.
## Dose Adjustments
* **Renal/Hepatic Impairment:** No formal dosage adjustments are provided in the product labeling; however, patients with pre-existing hepatic impairment may have an increased risk of elevated liver enzymes or sub-optimal expression and should be evaluated on a case-by-case basis.
* **Body Weight:** Dose is strictly based on total body weight.
## Contraindications
* Hypersensitivity to the active substance or any excipient.
* Active infection (acute or chronic systemic).
* Advanced hepatic fibrosis or cirrhosis.
## Adverse Effects
* **Hepatic:** Elevated ALT/AST (transaminase elevation is frequent and expected).
* **Infusion-related:** Nausea, vomiting, headache, fever, or tachycardia.
* **Immunological:** Development of anti-AAV antibodies (which may preclude efficacy).
* **Other:** Fatigue, arthralgia.
## Key Drug Interactions
* **Corticosteroids:** Concomitant use of prophylactic corticosteroids is standard to manage immune responses to the vector; monitor for steroid-related side effects.
* **Hepatotoxic agents:** Use caution with medications known to cause liver injury or those that induce/inhibit cytochrome P450 enzymes extensively, as they may complicate the monitoring of liver function post-infusion.
## Monitoring
* **Liver Enzymes (ALT/AST):** Weekly monitoring for at least the first 3–4 months post-infusion to detect immune-mediated hepatocyte clearance.
* **Factor IX Activity Levels:** Regularly monitor Factor IX levels to ensure therapeutic expression.
* **Immune Response:** Monitor for signs of potential loss of effect or infusion reactions.
## Clinical Pearls
* **Immunosuppression:** Patients require a course of prophylactic oral corticosteroids (e.g., prednisone/prednisolone) starting shortly before infusion to suppress the immune response against the AAV vector.
* **Irreversibility:** As this is a gene therapy, the procedure is irreversible. Ensure patients are fully counseled that follow-up monitoring for liver health and factor levels is mandatory.
* **Antibody Status:** Patients must be tested for pre-existing anti-AAV antibodies; those with high titers may not be eligible for therapy.
* **Administration:** Must be administered as a slow infusion by a specialized multidisciplinary team in a center experienced in hematology and clinical immunology.
***
**Educational Disclaimer:** This information is for educational purposes only and does not replace professional clinical judgment. Always consult the latest FDA-approved Prescribing Information (USPI) or your local Summary of Product Characteristics (SmPC) before ordering or administering this gene therapy, as protocols and safety data may be updated.
